Immune checkpoint inhibitor (ICI) therapies used to treat cancer come with the risk of adverse autoimmune responses, including arthritis that can persist for years and require joint replacement surgery. Little is known about the specific cells responsible for these events. Researchers at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, and collaborators led a study to investigate these immune adverse events and identified a specific type of CD8 T cell that characterizes inflammatory arthritis induced by ICI therapies.
Researchers studied T cells from a patient with severe ICI-arthritis who required bilateral knee replacements. In addition to these two joint tissue samples, they studied the fluid that accumulates within joints from an additional 23 patients with this condition and compared these samples to samples from patients with two common autoimmune conditions, rheumatoid arthritis or psoriatic arthritis. By comparing protein and gene expression levels across diseases, they were able to characterize unique immunological features of the CD8 T cells in ICI-arthritis. They further identified that a specific set of cytokines, type I interferons, can promote the CD8 T cell activation seen in ICI-arthritis.
Patients whose cancer was treated with ICI had high levels of this CD8 T cell type, and additional analysis revealed that the cells traveled between the joints and blood. Further, the T cells persisted in the bloodstream, providing one explanation for why ICI-arthritis continues even after ICI therapy is discontinued. Limitations include a small cohort of patients who are taking various treatments. Further research is needed to characterize how the CD8 T cells contribute to joint inflammation.
“Our results suggest that ICI therapy gives rise to a unique population of CD8 T cells in patients who develop ICI-arthritis,” said co-corresponding author Deepak A. Rao, MD, PhD, of the Brigham’s Division of Rheumatology, Inflammation, Immunity. “The immune events we characterized differ dramatically from the typical responses we have seen in autoimmune diseases like rheumatoid arthritis and psoriatic arthritis.”
Read more in Science Immunology.
Method of Research
Subject of Research
Clonally expanded CD38hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor–associated arthritis
Article Publication Date
D.A.R. reports personal fees from Pfizer, Janssen, Merck, GlaxoSmithKline, and Bristol-
Myers Squibb and grant support from Janssen and Bristol-Myers Squibb, outside the submitted
work. J.A.S. is funded by NIH/NIAMS (grant numbers R01 AR080659, R01 AR077607, P30
AR070253, and P30 AR072577), the R. Bruce and Joan M. Mickey Research Scholar Fund, and the
Llura Gund Award for Rheumatoid Arthritis Research and Care. J.A.S. reports research support
from Bristol Myers Squibb; consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol
Myers Squibb, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer, all unrelated to this work.
The funders had no role in the decision to publish or preparation of this article. The content is
solely the responsibility of the authors and does not necessarily represent the official views of
Harvard University, its affiliated academic health care centers, or the National Institutes of
Health. M.B.B. reports consulting fees from GlaxoSmithKline, 4FO Ventures, and Third Rock
Ventures and is consultant and founder of Mestag Therapeutics. M.A.P. reports consulting fees
from BMS, Merck, Novartis, Eisai, Pfizer, and Chugai and institutional support from RGenix,
Infinity, BMS, Merck, and Novartis. A.R.B. reports being a Member of the American College of
Rheumatology, Board of Directors from 2019 to 2022